Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation
Schvartsman G, Carneiro A, Filippi R, et al
Clinical Genitourinary Cancer, August 2019
DOI: 10.1016/j.clgc.2019.05.023
Clinical Practice Points
First-line treatment with nivolumab and ipilimumab for intermediate and high-risk patients with meta- static renal cell carcinoma (RCC) is standard-of- care.
The United States Food and Drug Administration extended approval to all RCC histologies, despite enrollment of clear-cell RCC only.
Sarcomatoid and rhabdoid dedifferentiation is associ- ated with significantly worse prognosis and may lead to increased programmed death-ligand 1 upregulation.
We present the first 2 cases, to our knowledge, of papillary RCC with sarcomatoid dedifferentiation with rapid and deep responses to the ipilimumab and nivolumab combination.
Read article
Sorry, the comment form is closed at this time.